Brief: Janux Therapeutics, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy
22/01/2026 12:11
Jan 22 (Reuters) - Janux Therapeutics Inc JANX.O: JANUX THERAPEUTICS ANNOUNCES COLLABORATION AND EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH BRISTOL MYERS SQUIBB TO DEVELOP A NOVEL TUMOR-ACTIVATED THERAPEUTIC FOR SOLID TUMORS JANUX THERAPEUTICS INC - TO RECEIVE UP TO $50 MILLION UPFRONT, $800 MILLION IN MILESTONES JANUX THERAPEUTICS: UNDER TERMS, CO IS ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY & COMMERCIAL MILESTONES UP TO ABOUT $800 MILLION IN AGGREGATE JANUX THERAPEUTICS INC - AS PART OF COLLABORATION, CO WILL COMPLETE PRECLINICAL DEVELOPMENT UP TO IND SUBMISSION JANUX THERAPEUTICS INC - AS PART OF COLLABORATION, BRISTOL WILL HOLD IND & BE RESPONSIBLE FOR SUBSEQUENT DEVELOPMENT & GLOBAL COMMERCIALIZATION JANUX THERAPEUTICS INC - CO ALSO ENTITLED TO TIERED ROYALTIES ON GLOBAL SALES Source text: ID:nBw1sx9M9a Further company coverage: JANX.O ((Reuters.Briefs@thomsonreuters.com;))